Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

Dexamethasone 4ruxolitinib 2pomalidomide 2daratumumab 2Tacrolimus 2Mycophenolic Acid 2Lenalidomide 2Cyclophosphamide 2Bortezomib 2sonidegib 1ricolinostat 1ponatinib 1nirogacestat 1fludarabine phosphate 1fludarabine 1dacetuzumab 1Vorinostat 1Stem Cell Transplantation 1Remifentanil 1Quality of Life 1Methotrexate 1Mesna 1Melphalan 1KW-2478 1Hsp90 inhibitor KU757 1Filgrastim 1Electrocardiography 1Cyclosporine 1Clinical Laboratory Techniques 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Diseases × dacetuzumab × Clear all
NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡